^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy.

Published date:
01/11/2021
Excerpt:
Eighty-one (77.1%) of 105 patients provided material for this analysis. A lower pre-treatment expression of TYMS was associated with clinical benefit (PR and SD; p = 0.021). 
Secondary therapy:
5-fluorouracil + oxaliplatin + arfolitixorin
Trial ID: